# Vion Pharmaceuticals

Source: https://onco.cc/companies/vion-pharmaceuticals/  
OnCo record `vion-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Vion was a Yale spin-out whose alkylating agent laromustine reached phase 3 in older patients with acute myeloid leukaemia but was not approved; the company filed for bankruptcy in 2009.

## Summary

Vion Pharmaceuticals, founded in 1992 in New Haven, Connecticut, from Yale University research, developed laromustine (Onrigin), a sulfonylhydrazine alkylating agent, for acute myeloid leukaemia in patients unfit for intensive chemotherapy. The FDA declined approval without a randomised trial and Vion filed for Chapter 11 bankruptcy in 2009. Its trials remain on ClinicalTrials.gov under Vion as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Vion Pharmaceuticals, Inc.; Vion
- Tags: ctgov-sponsor
- HQ: New Haven, CT
- Type: biotech
- Website: http://www.vionpharm.com

## Sources

- Official website: http://www.vionpharm.com
- ClinicalTrials.gov: trials led by Vion Pharmaceuticals, Inc.: https://clinicaltrials.gov/search?lead=Vion%20Pharmaceuticals%2C%20Inc.
- Wikidata: https://www.wikidata.org/wiki/Q7933401

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/vion-pharmaceuticals.json